Bristol Myers Squibb’s Breyanzi Approved by the U.S. FDA as the First and Only CAR T Cell Therapy...

Bristol Myers Squibb’s Breyanzi Approved by the U.S. FDA as the First and Only CAR T Cell Therapy for Adults with Relapsed or Refractory Marginal Zone Lymphoma (MZL)  Bristol Myers Squibb

BMS Holdings Berhad Celebrates Successful ACE Market Debut On Bursa Malaysia - Yahoo Finance

BMS Holdings Berhad Celebrates Successful ACE Market Debut On Bursa Malaysia  Yahoo Finance

With site 'irregularities,' Bristol Myers delays key Cobenfy readout in Alzheimer's psychosis - F...

With site 'irregularities,' Bristol Myers delays key Cobenfy readout in Alzheimer's psychosis  Fierce Pharma

BMS Delays Cobenfy Alzheimer’s Psychosis Data After ‘Irregularities’ in Phase III Study - BioSpace

BMS Delays Cobenfy Alzheimer’s Psychosis Data After ‘Irregularities’ in Phase III Study  BioSpace

Daikin set to buy Vietnamese BMS provider - Cooling Post

Daikin set to buy Vietnamese BMS provider  Cooling Post

SABCS25: BioNTech, BMS flex upbeat interim mid-stage data for PD-L1/VEGF-A in TNBC - FirstWord Ph...

SABCS25: BioNTech, BMS flex upbeat interim mid-stage data for PD-L1/VEGF-A in TNBC  FirstWord Pharma

Cambridge biotech receives $255M in sale of spinout to BMS - The Business Journals

Cambridge biotech receives $255M in sale of spinout to BMS  The Business Journals

Merck, Bristol Myers Squibb plan NJ layoffs (updated) - NJBIZ

Merck, Bristol Myers Squibb plan NJ layoffs (updated)  NJBIZ

Bristol Myers Squibb Foundation Awards Grant to PATH to Improve Care for Inherited Blood Disorder...

Bristol Myers Squibb Foundation Awards Grant to PATH to Improve Care for Inherited Blood Disorders in India  CSRwire

FDA Approves BMS’s Liso-Cel for R/R Marginal Zone Lymphoma - CGTLive®

FDA Approves BMS’s Liso-Cel for R/R Marginal Zone Lymphoma  CGTLive®

Bristol Myers must face $6.7 billion lawsuit over delayed cancer drug, US judge rules - Reuters

Bristol Myers must face $6.7 billion lawsuit over delayed cancer drug, US judge rules  Reuters

CAR T cell therapy patient resources - Bristol Myers Squibb

CAR T cell therapy patient resources  Bristol Myers Squibb

Texas files suit against Sanofi, BMS over 'deceptive' Plavix marketing - Fierce Pharma

Texas files suit against Sanofi, BMS over 'deceptive' Plavix marketing  Fierce Pharma

BioNTech and BMS’ bispecific touts 59.3% nine-month PFS in TNBC - Yahoo

BioNTech and BMS’ bispecific touts 59.3% nine-month PFS in TNBC  Yahoo

Merck & Co., BMS to lay off over 300 staffers in New Jersey - FirstWord Pharma

Merck & Co., BMS to lay off over 300 staffers in New Jersey  FirstWord Pharma

Chris Shibutani, MD - Bristol Myers Squibb

Chris Shibutani, MD  Bristol Myers Squibb

Our technologies - Bristol Myers Squibb

Our technologies  Bristol Myers Squibb

Transparency & reporting - Bristol Myers Squibb

Transparency & reporting  Bristol Myers Squibb

Champions in Care - Bristol Myers Squibb

Champions in Care  Bristol Myers Squibb

Our research in neuroscience - Bristol Myers Squibb

Our research in neuroscience  Bristol Myers Squibb

Empowering patients with clarity & confidence through UPL program - Bristol Myers Squibb

Empowering patients with clarity & confidence through UPL program  Bristol Myers Squibb

Driving patient-centric care through global patient outreach - Bristol Myers Squibb

Driving patient-centric care through global patient outreach  Bristol Myers Squibb

Q&A with Robert Plenge: What is Bristol Myers Squibb’s research strategy and where are we taking ...

Q&A with Robert Plenge: What is Bristol Myers Squibb’s research strategy and where are we taking it?  Bristol Myers Squibb

Science Firsthand: The renaissance of neuroscience R&D - Bristol Myers Squibb

Science Firsthand: The renaissance of neuroscience R&D  Bristol Myers Squibb

BMS scores 5th indication for Breyanzi with FDA marginal zone lymphoma nod - Fierce Pharma

BMS scores 5th indication for Breyanzi with FDA marginal zone lymphoma nod  Fierce Pharma

RayzeBio’s new hub revolutionizes cancer treatment with next-gen RPTs - Bristol Myers Squibb

RayzeBio’s new hub revolutionizes cancer treatment with next-gen RPTs  Bristol Myers Squibb

I-See-BMs: Chinese Nuclear Policy Under Xi Jinping - Foreign Policy Research Institute

I-See-BMs: Chinese Nuclear Policy Under Xi Jinping  Foreign Policy Research Institute

"Too many patients in rural America face barriers to cardiovascular care — barriers that - Bristo...

"Too many patients in rural America face barriers to cardiovascular care — barriers that  Bristol Myers Squibb

T20 World Cup tickets: 'ScamMyShow' — BMS faces fans' ire over long queues, wait time, 'website c...

T20 World Cup tickets: 'ScamMyShow' — BMS faces fans' ire over long queues, wait time, 'website crash'  MSN

BMS and J&J's blood thinner flunks phase 3, denting big blockbuster hopes - Fierce Biotech

BMS and J&J's blood thinner flunks phase 3, denting big blockbuster hopes  Fierce Biotech

Bristol Myers Squibb CEO Chris Boerner says company culture was the missing piece of his ‘patent ...

Bristol Myers Squibb CEO Chris Boerner says company culture was the missing piece of his ‘patent cliff’ plan  Fortune

FDA Fast Tracks Anti-MTBR-Tau-Targeting Antibody BMS-986446 for Alzheimer Disease - NeurologyLive

FDA Fast Tracks Anti-MTBR-Tau-Targeting Antibody BMS-986446 for Alzheimer Disease  NeurologyLive

Bristol-Myers Squibb Stock (BMY) News, Forecasts and Analysis for Dec. 12, 2025: Dividend Hike, F...

Bristol-Myers Squibb Stock (BMY) News, Forecasts and Analysis for Dec. 12, 2025: Dividend Hike, FDA Updates, and Wall Street's 2026 Focus  ts2.tech

BMS and Johnson & Johnson terminate Phase III ACS trial due to likely failure - Clinical Trials A...

BMS and Johnson & Johnson terminate Phase III ACS trial due to likely failure  Clinical Trials Arena

BMS, J&J's FXIa inhibitor milvexian fails first pivotal test - FirstWord Pharma

BMS, J&J's FXIa inhibitor milvexian fails first pivotal test  FirstWord Pharma

From IMiDs to CELMoDs: Pioneering next generation treatments for blood cancer - Bristol Myers Squibb

From IMiDs to CELMoDs: Pioneering next generation treatments for blood cancer  Bristol Myers Squibb

BMS’ Phase III trial of Reblozyl misses primary endpoint - Clinical Trials Arena

BMS’ Phase III trial of Reblozyl misses primary endpoint  Clinical Trials Arena

BioNTech and BMS Report Promising Phase 2 Results for TNBC Treatment - TipRanks

BioNTech and BMS Report Promising Phase 2 Results for TNBC Treatment  TipRanks

BMS Makes $1.5B Cell Therapy Play With Orbital Takeover - BioSpace

BMS Makes $1.5B Cell Therapy Play With Orbital Takeover  BioSpace

Psoriasis around the world - Bristol Myers Squibb

Psoriasis around the world  Bristol Myers Squibb

BMS and Takeda dive into AI data pool, joining peers in collaborative push to unfold the future -...

BMS and Takeda dive into AI data pool, joining peers in collaborative push to unfold the future  Fierce Biotech

BMS removes 2 clinical programs from pipeline, one from Mirati and another from Exscientia - Fier...

BMS removes 2 clinical programs from pipeline, one from Mirati and another from Exscientia  Fierce Biotech

Next-generation blood thinner from Bristol Myers Squibb, J&J fails key trial - statnews.com

Next-generation blood thinner from Bristol Myers Squibb, J&J fails key trial  statnews.com

300+ employees from 33 nations will cycle to advance cancer research, celebrating 12 years of C2C...

300+ employees from 33 nations will cycle to advance cancer research, celebrating 12 years of C2C4C  Bristol Myers Squibb

Bristol Myers Squibb Announces Dividend Increase - Yahoo Finance

Bristol Myers Squibb Announces Dividend Increase  Yahoo Finance

Bristol Myers Squibb Commits to Veeva Vault CRM - Veeva

Bristol Myers Squibb Commits to Veeva Vault CRM  Veeva

Nurse practitioners impact patient care and foster collaboration - Bristol Myers Squibb

Nurse practitioners impact patient care and foster collaboration  Bristol Myers Squibb

Honoring oncologists through the Time Back campaign - Bristol Myers Squibb

Honoring oncologists through the Time Back campaign  Bristol Myers Squibb

Our science - Bristol Myers Squibb

Our science  Bristol Myers Squibb

Rovi acquires BMS facility in Phoenix and strikes $250M manufacturing deal - Fierce Pharma

Rovi acquires BMS facility in Phoenix and strikes $250M manufacturing deal  Fierce Pharma

BMS boosts cancer trials with Sarah Cannon's clinical research platform - Fierce Biotech

BMS boosts cancer trials with Sarah Cannon's clinical research platform  Fierce Biotech

BMS, Bain Capital team up on autoimmune-focused newco - FirstWord Pharma

BMS, Bain Capital team up on autoimmune-focused newco  FirstWord Pharma

BMS builds a 'world of gratitude' to honor healthcare workers in new PSA - Fierce Pharma

BMS builds a 'world of gratitude' to honor healthcare workers in new PSA  Fierce Pharma

A global journey through BMS’ R&D hubs - Bristol Myers Squibb

A global journey through BMS’ R&D hubs  Bristol Myers Squibb

Ono's BMS-partnered EP4 antagonist improves progression-free survival in phase 2 gastric cancer t...

Ono's BMS-partnered EP4 antagonist improves progression-free survival in phase 2 gastric cancer test  Fierce Biotech

Bristol Myers Squibb and TV Host Gail Simmons Tackle Stigma in Schizophrenia with New Initiative ...

Bristol Myers Squibb and TV Host Gail Simmons Tackle Stigma in Schizophrenia with New Initiative Spotlighting the Power of Support and Connection  Bristol Myers Squibb

Our impact - Bristol Myers Squibb

Our impact  Bristol Myers Squibb

BMS' hyped schizophrenia med Cobenfy delivers so-so launch year as execs map plan for future - Fi...

BMS' hyped schizophrenia med Cobenfy delivers so-so launch year as execs map plan for future  Fierce Pharma

ESMO: BMS looks to 'stay ahead of the competition' with ADC's 55% response rate in early-stage tr...

ESMO: BMS looks to 'stay ahead of the competition' with ADC's 55% response rate in early-stage trial  Fierce Biotech

BMS expands CAR-T portfolio with $1.5bn Orbital buyout - Pharmaceutical Technology

BMS expands CAR-T portfolio with $1.5bn Orbital buyout  Pharmaceutical Technology

BMS Deepens ALS Alliance With Insitro, Puts $2B+ On the Line - BioSpace

BMS Deepens ALS Alliance With Insitro, Puts $2B+ On the Line  BioSpace

BMS Jettisons Coronary Trial for J&J-Partnered Anticoagulant - BioSpace

BMS Jettisons Coronary Trial for J&J-Partnered Anticoagulant  BioSpace

BMS, BioNTech Post Geographically Consistent Mid-Stage PD-L1/VEGF Data in SCLC - BioSpace

BMS, BioNTech Post Geographically Consistent Mid-Stage PD-L1/VEGF Data in SCLC  BioSpace

BMS plots another DTC platform, this one offering Sotyktu at 86% discount to cash-pay patients - ...

BMS plots another DTC platform, this one offering Sotyktu at 86% discount to cash-pay patients  Fierce Pharma

BMS Expands Patient Options With Direct-to-Patient Platform - Dermatology Times

BMS Expands Patient Options With Direct-to-Patient Platform  Dermatology Times

Doctorx Unscripted Bold Conversations about Patient-Driven Science - Bristol Myers Squibb

Doctorx Unscripted Bold Conversations about Patient-Driven Science  Bristol Myers Squibb

Introducing Workforce Planner: Your hub for managing people and projects in Kaseya BMS - Kaseya

Introducing Workforce Planner: Your hub for managing people and projects in Kaseya BMS  Kaseya

BMS inks $1.5B in vivo CAR-T buyout to pull Orbital into its sphere of influence - Fierce Biotech

BMS inks $1.5B in vivo CAR-T buyout to pull Orbital into its sphere of influence  Fierce Biotech

BMS, Pfizer launch direct-to-consumer push for Eliquis in the US - FirstWord Pharma

BMS, Pfizer launch direct-to-consumer push for Eliquis in the US  FirstWord Pharma

Bristol-Myers Squibb: Cheap For A Reason (NYSE:BMY) - Seeking Alpha

Bristol-Myers Squibb: Cheap For A Reason (NYSE:BMY)  Seeking Alpha

Biokin, having landed BMS deal, posts ph. 3 cancer win for bispecific ADC - Fierce Biotech

Biokin, having landed BMS deal, posts ph. 3 cancer win for bispecific ADC  Fierce Biotech

BMS to close Illinois site as part of cell therapy manufacturing consolidation - FirstWord Pharma

BMS to close Illinois site as part of cell therapy manufacturing consolidation  FirstWord Pharma

Bristol Myers Squibb CDTO Greg Meyers on biopharma’s AI-enabled future - McKinsey & Company

Bristol Myers Squibb CDTO Greg Meyers on biopharma’s AI-enabled future  McKinsey & Company

Bristol Myers Squibb Spins Out Immunology Assets into New Company Backed by Bain Capital - PharmE...

Bristol Myers Squibb Spins Out Immunology Assets into New Company Backed by Bain Capital  PharmExec.com

BMS ups guidance, but its financial prospects fail to capture investor enthusiasm - FirstWord Pharma

BMS ups guidance, but its financial prospects fail to capture investor enthusiasm  FirstWord Pharma

BMS sells controlling stake in historic US-China pharmaceutical joint venture - Fierce Pharma

BMS sells controlling stake in historic US-China pharmaceutical joint venture  Fierce Pharma

Endocannabinoid signaling and the role of FAAH and MAGL fact sheet - Bristol Myers Squibb

Endocannabinoid signaling and the role of FAAH and MAGL fact sheet  Bristol Myers Squibb

Shaping a new era in cancer research - Bristol Myers Squibb

Shaping a new era in cancer research  Bristol Myers Squibb

BMS shuffles R&D leadership, bringing in AstraZeneca exec as new CMO - FirstWord Pharma

BMS shuffles R&D leadership, bringing in AstraZeneca exec as new CMO  FirstWord Pharma

ASH: BMS’s Iberdomide Shows Efficacy In Myeloma Maintenance - Citeline News & Insights

ASH: BMS’s Iberdomide Shows Efficacy In Myeloma Maintenance  Citeline News & Insights

Bristol Myers midtrial endpoint addition secures phase 3 win in multiple myeloma - Fierce Biotech

Bristol Myers midtrial endpoint addition secures phase 3 win in multiple myeloma  Fierce Biotech

Post study drug access to BMS investigational medicinal products and approved products - Bristol ...

Post study drug access to BMS investigational medicinal products and approved products  Bristol Myers Squibb

BMS Battles ‘Deeply Ingrained’ Prescribing Habits in Schizophrenia as Cobenfy Misses Q3 Estimates...

BMS Battles ‘Deeply Ingrained’ Prescribing Habits in Schizophrenia as Cobenfy Misses Q3 Estimates  BioSpace

Bristol Myers Squibb to buy RNA start-up for $1.5 billion - C&EN

Bristol Myers Squibb to buy RNA start-up for $1.5 billion  C&EN

Fierce Pharma Asia—BMS' China asset sale; 2 biotech debuts; 2 potential deals - Fierce Pharma

Fierce Pharma Asia—BMS' China asset sale; 2 biotech debuts; 2 potential deals  Fierce Pharma

Bristol Myers, Pfizer offer Eliquis at a discount through DTC online program - Fierce Pharma

Bristol Myers, Pfizer offer Eliquis at a discount through DTC online program  Fierce Pharma

Expanding access to lung cancer screening - Bristol Myers Squibb

Expanding access to lung cancer screening  Bristol Myers Squibb

New BMS Department Head Makes Enthusiastic Return to Purdue to Take on New Leadership Role - Purd...

New BMS Department Head Makes Enthusiastic Return to Purdue to Take on New Leadership Role  Purdue University College of Veterinary Medicine

BMS, RayzeBio launch radiopharmaceutical manufacturing site in Indianapolis - Fierce Pharma

BMS, RayzeBio launch radiopharmaceutical manufacturing site in Indianapolis  Fierce Pharma

Déjà vu for Bristol Myers as it faces another anti-competition lawsuit over blockbuster Pomalyst ...

Déjà vu for Bristol Myers as it faces another anti-competition lawsuit over blockbuster Pomalyst  Fierce Pharma

FDA Action Alert: BMS, Bayer, Arrowhead and More - BioSpace

FDA Action Alert: BMS, Bayer, Arrowhead and More  BioSpace

Career oncologist makes Big Pharma leap to BMS—Chutes & Ladders - Fierce Biotech

Career oncologist makes Big Pharma leap to BMS—Chutes & Ladders  Fierce Biotech

In UK, Big Pharma pressure campaign rolls on as Bristol Myers plans US-level pricing for Cobenfy ...

In UK, Big Pharma pressure campaign rolls on as Bristol Myers plans US-level pricing for Cobenfy  Fierce Pharma

BMS, BioNTech Ink Up-to-$11B Cancer Bispecific Antibody Collaboration - Genetic Engineering and B...

BMS, BioNTech Ink Up-to-$11B Cancer Bispecific Antibody Collaboration  Genetic Engineering and Biotechnology News

Policy shows how BMS MLB game qualifies for $4.8M grant - WJHL

Policy shows how BMS MLB game qualifies for $4.8M grant  WJHL

Bristol Myers Squibb Appoints Cari Gallman as Executive Vice President, General Counsel and Chief...

Bristol Myers Squibb Appoints Cari Gallman as Executive Vice President, General Counsel and Chief Policy Officer  Bristol Myers Squibb

Why A Surprise Delay For Cobenfy Just Sparked Bristol Myers Stock - Investor's Business Daily

Why A Surprise Delay For Cobenfy Just Sparked Bristol Myers Stock  Investor's Business Daily

Women innovators in AI transforming patient care - Bristol Myers Squibb

Women innovators in AI transforming patient care  Bristol Myers Squibb

BMS-986446 Granted Fast Track Designation for the Treatment of Alzheimer Disease - Psychiatric Times

BMS-986446 Granted Fast Track Designation for the Treatment of Alzheimer Disease  Psychiatric Times

Bristol Myers touts commercial execution, reckons with recent clinical setbacks - Fierce Pharma

Bristol Myers touts commercial execution, reckons with recent clinical setbacks  Fierce Pharma